In recent years, combination therapy has gained attention for improving hepatocellular carcinoma (HCC) treatment. However, the anticancer potential of marine-derived proteins combined with sorafenib remains largely unexplored. This study investigates, for the first time, the anticancer effects and mechanisms of Symplectoteuthis oualaniensis protamine (SOP), its PEG-modified form (SOP-PEG), and sorafenib in Hepa1-6 cells. Flow cytometry, Western blotting, and immunohistochemistry were employed to assess their effects on cell proliferation, cycle progression, apoptosis, and PI3K-Akt signaling. The IC₅₀ values of SOP, SOP-PEG, and sorafenib against Hepa1-6 cells were 10.14 μM, 9.23 μM, and 1.85 μM, respectively. Importantly, SOP and SOP-PEG showed no cytotoxicity toward LO2 normal liver cells within 0-10 μM. Combination treatments significantly suppressed Hepa1-6 cell proliferation and induced apoptosis. Notably, SOP-PEG combined with sorafenib led to the highest apoptotic rate (50.1 %), outperforming the SOP plus sorafenib group (43.8 %). The combination also inhibited PI3K-Akt pathway activation, disrupting proliferative and anti-apoptotic signaling. SOP-PEG plus sorafenib demonstrated superior efficacy compared to either agent alone. This study presents a promising therapeutic strategy for HCC by integrating naturally derived proteins with chemotherapy.